Future oncology
-
Randomized Controlled Trial Multicenter Study
Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial.
Gastric cancer is a highly aggressive disease. In metastatic setting, median overall survival, even with modern chemotherapy regimens, generally does not exceed 1 year and toxicity is a major concern. ⋯ Unlike traditional chemotherapy, treatment with ramucirumab was associated with very few toxic effects. This article will review the main findings of the REGARD trial and discuss their potential impact on future treatment of metastatic gastric cancer.